271 related articles for article (PubMed ID: 19192274)
1. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration.
Andreas K; Häupl T; Lübke C; Ringe J; Morawietz L; Wachtel A; Sittinger M; Kaps C
Arthritis Res Ther; 2009; 11(1):R15. PubMed ID: 19192274
[TBL] [Abstract][Full Text] [Related]
2. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study.
Andreas K; Lübke C; Häupl T; Dehne T; Morawietz L; Ringe J; Kaps C; Sittinger M
Arthritis Res Ther; 2008; 10(1):R9. PubMed ID: 18205922
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs.
Häupl T; Yahyawi M; Lübke C; Ringe J; Rohrlach T; Burmester GR; Sittinger M; Kaps C
J Biomol Screen; 2007 Apr; 12(3):328-40. PubMed ID: 17379860
[TBL] [Abstract][Full Text] [Related]
4. Aurothiomalate inhibits cyclooxygenase 2, matrix metalloproteinase 3, and interleukin-6 expression in chondrocytes by increasing MAPK phosphatase 1 expression and decreasing p38 phosphorylation: MAPK phosphatase 1 as a novel target for antirheumatic drugs.
Nieminen R; Korhonen R; Moilanen T; Clark AR; Moilanen E
Arthritis Rheum; 2010 Jun; 62(6):1650-9. PubMed ID: 20178133
[TBL] [Abstract][Full Text] [Related]
5. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
6. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium.
Bramlage CP; Kaps C; Ungethüm U; Bramlage P; Koziolek M; Wessels J; Krenn V; Pruss A; Müller GA; Strutz F; Burmester GR; Häupl T
Scand J Rheumatol; 2008; 37(6):401-9. PubMed ID: 18830904
[TBL] [Abstract][Full Text] [Related]
7. Aurothiomalate inhibits COX-2 expression in chondrocytes and in human cartilage possibly through its effects on COX-2 mRNA stability.
Nieminen R; Vuolteenaho K; Riutta A; Kankaanranta H; van der Kraan PM; Moilanen T; Moilanen E
Eur J Pharmacol; 2008 Jun; 587(1-3):309-16. PubMed ID: 18448096
[TBL] [Abstract][Full Text] [Related]
8. In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage.
Pretzel D; Pohlers D; Weinert S; Kinne RW
Arthritis Res Ther; 2009; 11(1):R25. PubMed ID: 19226472
[TBL] [Abstract][Full Text] [Related]
9. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
10. A 3D cartilage - inflammatory cell culture system for the modeling of human osteoarthritis.
Sun L; Wang X; Kaplan DL
Biomaterials; 2011 Aug; 32(24):5581-9. PubMed ID: 21565399
[TBL] [Abstract][Full Text] [Related]
11. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts.
Petrow PK; Hummel KM; Schedel J; Franz JK; Klein CL; Müller-Ladner U; Kriegsmann J; Chang PL; Prince CW; Gay RE; Gay S
Arthritis Rheum; 2000 Jul; 43(7):1597-605. PubMed ID: 10902765
[TBL] [Abstract][Full Text] [Related]
12. Aurothiomalate inhibits the expression of mPGES-1 in primary human chondrocytes.
Tuure L; Hämäläinen M; Moilanen T; Moilanen E
Scand J Rheumatol; 2015; 44(1):74-9. PubMed ID: 25314295
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase 10 promotion of collagenolysis via procollagenase activation: implications for cartilage degradation in arthritis.
Barksby HE; Milner JM; Patterson AM; Peake NJ; Hui W; Robson T; Lakey R; Middleton J; Cawston TE; Richards CD; Rowan AD
Arthritis Rheum; 2006 Oct; 54(10):3244-53. PubMed ID: 17009259
[TBL] [Abstract][Full Text] [Related]
14. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis.
Vandooren B; Cantaert T; van Lierop MJ; Bos E; De Rycke L; Veys EM; De Keyser F; Bresnihan B; Luyten FP; Verdonk PC; Tak PP; Boots AH; Baeten D
Ann Rheum Dis; 2009 Jun; 68(6):1044-50. PubMed ID: 18633128
[TBL] [Abstract][Full Text] [Related]
15. Synovial fibroblast-derived exosomal microRNA-106b suppresses chondrocyte proliferation and migration in rheumatoid arthritis via down-regulation of PDK4.
Liu D; Fang Y; Rao Y; Tan W; Zhou W; Wu X; Zhang C; Zhang Y; Liu Y; Sunagawa M; Hisamitsu T; Li G
J Mol Med (Berl); 2020 Mar; 98(3):409-423. PubMed ID: 32152704
[TBL] [Abstract][Full Text] [Related]
16. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
17. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.
Moran EM; Mullan R; McCormick J; Connolly M; Sullivan O; Fitzgerald O; Bresnihan B; Veale DJ; Fearon U
Arthritis Res Ther; 2009; 11(4):R113. PubMed ID: 19627579
[TBL] [Abstract][Full Text] [Related]
18. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand.
Lee CK; Lee EY; Chung SM; Mun SH; Yoo B; Moon HB
Arthritis Rheum; 2004 Dec; 50(12):3831-43. PubMed ID: 15593184
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-1 and anti-CD44 interventions producing significant inhibition of cartilage destruction in an in vitro model of cartilage invasion by rheumatoid arthritis synovial fibroblasts.
Neidhart M; Gay RE; Gay S
Arthritis Rheum; 2000 Aug; 43(8):1719-28. PubMed ID: 10943861
[TBL] [Abstract][Full Text] [Related]
20. α-Melanocyte-stimulating-hormone (α-MSH) modulates human chondrocyte activation induced by proinflammatory cytokines.
Capsoni F; Ongari AM; Lonati C; Accetta R; Gatti S; Catania A
BMC Musculoskelet Disord; 2015 Jun; 16():154. PubMed ID: 26093672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
